Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Optimization of stem cell fitness and mobilization using moderate transfusion and an oral anti-sickling agent in the sickle mouse model.

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJon WadeAPAshwin PatelLWLawrence J. Wilson

Discussion

Loading...

Member takes

Overview

Experiments show transfusion therapy and osivelotor improve HSC fitness in sickle cell mice, indicating better gene therapy outcomes.

Key Points

  • Assess the effects of moderate transfusion and osivelotor on stem cell mobilization and fitness in sickle cell disease.
  • Used Townes sickle mouse model for experimental treatments.
  • Administered moderate chronic transfusion therapy and oral osivelotor.
  • Conducted flow cytometry to quantify hematopoietic stem progenitor cells and engraftment assays.
  • Osivelotor improved Hb levels significantly compared to untreated mice.
  • CTT resulted in higher engraftment rates than untreated controls.
  • Osivelotor conditioning increased mobilized LSKs compared to untreated controls.

Cite This Study

Wade et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e48bhttps://doi.org/10.1182/blood-2025-1150
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study2025 · 2 citations
  2. 2Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients2025
  3. 3Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease2025
  4. 4Targeting hemolysis and raas: Osivelotor and losartan ameliorate sickle cell renal pathology2025
  5. 5Non-genotoxic conditioning to increase donor chimerism levels in a mismatched murine transplant model for sickle cell disease2025